Similarly, treatment with recombinant endostatin, a matrikine derived from collagen XVIII, has been shown to prevent allergen-induced airway hyperresponsiveness, airway inflammation and expression of inflammatory mediators [76]. The gene discussed is COL18A1; the disease is airway hyperresponsiveness.